JP2012525437A5 - - Google Patents

Info

Publication number

JP2012525437A5

JP2012525437A5 JP2012508764A JP2012508764A JP2012525437A5 JP 2012525437 A5 JP2012525437 A5 JP 2012525437A5 JP 2012508764 A JP2012508764 A JP 2012508764A JP 2012508764 A JP2012508764 A JP 2012508764A JP 2012525437 A5 JP2012525437 A5 JP 2012525437A5

Authority

JP

Japan

Prior art keywords

compound

purin

dihydroxytetrahydrofuran

formula

bicyclic

Prior art date

2010-04-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims 35
• LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 claims 9
• 230000004410 intraocular pressure Effects 0.000 claims 6
• 125000000217 alkyl group Chemical group 0.000 claims 5
• 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 5
• 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 4
• AQLVRTWKJDTWQQ-SDBHATRESA-N [(2r,3s,4r,5r)-5-[6-(cyclopentylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl nitrate Chemical compound O[C@@H]1[C@H](O)[C@@H](CO[N+]([O-])=O)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 AQLVRTWKJDTWQQ-SDBHATRESA-N 0.000 claims 3
• 125000002619 bicyclic group Chemical group 0.000 claims 3
• 125000000753 cycloalkyl group Chemical group 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 125000002950 monocyclic group Chemical group 0.000 claims 3
• 239000008194 pharmaceutical composition Substances 0.000 claims 3
• 150000003839 salts Chemical class 0.000 claims 3
• DZXBHDRHRFLQCJ-UHFFFAOYSA-M sodium;methyl sulfate Chemical compound [Na+].COS([O-])(=O)=O DZXBHDRHRFLQCJ-UHFFFAOYSA-M 0.000 claims 3
• 239000000556 agonist Substances 0.000 claims 2
• 239000003795 chemical substances by application Substances 0.000 claims 2
• 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
• CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 claims 2
• 125000001475 halogen functional group Chemical group 0.000 claims 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims 2
• 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 1
• 229940126062 Compound A Drugs 0.000 claims 1
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
• 102000004310 Ion Channels Human genes 0.000 claims 1
• 206010067013 Normal tension glaucoma Diseases 0.000 claims 1
• 206010030348 Open-Angle Glaucoma Diseases 0.000 claims 1
• 206010036790 Productive cough Diseases 0.000 claims 1
• 239000005557 antagonist Substances 0.000 claims 1
• 239000002876 beta blocker Substances 0.000 claims 1
• 229940097320 beta blocking agent Drugs 0.000 claims 1
• 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 1
• JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 claims 1
• 230000001771 impaired effect Effects 0.000 claims 1
• 239000007924 injection Substances 0.000 claims 1
• 238000002347 injection Methods 0.000 claims 1
• 201000002978 low tension glaucoma Diseases 0.000 claims 1
• JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims 1
• 239000003604 miotic agent Substances 0.000 claims 1
• 239000000203 mixture Substances 0.000 claims 1
• 239000003607 modifier Substances 0.000 claims 1
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
• 239000004090 neuroprotective agent Substances 0.000 claims 1
• 239000002504 physiological saline solution Substances 0.000 claims 1
• 150000003180 prostaglandins Chemical class 0.000 claims 1
• LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims 1
• 239000003590 rho kinase inhibitor Substances 0.000 claims 1
• 210000003802 sputum Anatomy 0.000 claims 1
• 208000024794 sputum Diseases 0.000 claims 1
• 230000000699 topical effect Effects 0.000 claims 1
• ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1